Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene

NCT06891443 is registered in ClinicalTrials.gov with Laboratoires Thea as lead sponsor.

NCT NCT06891443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06891443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Masked, Randomized, Placebo-Controlled, Paired-Eye Study to Evaluate the Efficacy, Safety and Tolerability of Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Due to the c.2991+1655A>G (p.Cys998X) Mutation in the CEP290 Gene
Lead sponsor
Laboratoires Thea
Phase
Phase 3
Overall status
Recruiting
Start date
June 4, 2025
Completion date
October 31, 2028
Enrollment
32 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

blindness, eye diseases, eye diseases, hereditary, eye disorders congenital, leber congenital amaurosis, leber congenital amaurosis 10, neurological manifestations, retinal disease, sensation disorders, vision disorder